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Michael J. Welch, Ph.D., Recipient of the Aebersold Award

Aebersold Award To Dr. Michael J. Welch
Note from the Director of Mallinckrodt Institute, Ronald G.
Evens, M.D.
The following article announces the awarding of a prestigious honor to Michael J. Welch, Ph.D., Professor of Radiology
at the Mallinckrodt Institute and Washington University. This
is the highest recognition for science bestowed by the Society
of Nuclear Medicine. Mike Welch's recognition is well-deserved
because of his many contributions to the development of
short-lived radiopharmaceuticals, their clinical use, and the
training of many scientists in this field. The Mallinckrodt
Institute and Washington University take great pride in the
recognition of Dr. Welch and are particularly pleased that two
of only eight recipients of the Aebersold Award are from this
Institution.

The Society of Nuclear Medicine has honored Dr.
Michael J. Welch, Professor of Radiology and Chemistry at Mallinckrodt Institute and Washington University for his pioneering role as the first hot-atom
chemist to become involved in using a cyclotron to
make very short-lived radio-pharmaceuticals for nuclear medicine. Dr. Welch is the recipient of the
Society's prestigious Paul C. Aebersold Award which
was presented to him at the 27th annual meeting of
the Society of Nuclear Medicine, June 24-27, in
Detroit.
The Society of Nuclear Medicine is an organization
of more than 10,000 physicians, scientists, and
technologists. In selecting Dr. Welch, the awards
committee took into consideration not only his
extensive research contributions in radiopharmaceutical chemistry, but also his equally noteworthy
efforts in clinical research, patient care, and teaching.
Other recipients, since the award was first presented in 1973, include Dr. Michel Ter-Pogossian
(1976) for the development of the Positron Emission
Transverse Tomography (PETT) system, making Mallinckrodt the only medical institution with two
recipients. This year, the award includes a plaque of
citation praising Dr. Welch for his outstanding
achievements in basic science applied to nuclear
medicine.

Dr. Welch was awarded the B.A. and M.A. degrees
from Cambridge University, England. In 1965, having
received his Ph.D. degree on the chemistry of hot|
tritium atoms from the University of London, he
went on to Brookhaven National Laboratory to begin
a two year fellowship with Alfred P. Wolf, studying
the chemistry of hot carbon atoms. Entering the field
of nuclear medicine in 1967, when he joined the staff
of Mallinckrodt Institute of Radiology, Dr. Welch
began an effective, far-sighted program of research
involving short-lived cyclotron-produced radio
pharmaceuticals. As a result, the Institute can count
several firsts in the clinical use of positron emitters.
Dr. Welch's early research led to the production of
simple molecules synthesized directly in the cyclo
tron target, but by utilizing clever techniques, he
soon was able to synthesize more complex radiophar
maceuticals for application in nuclear medicine. His
C-glucose for the measurement of cerebral metabo
lism synthesis represents a benchmark study ir
nuclear medicine. For the first time, a cyclotron was
used to prepare a precursor which was used foi
biosynthesis of a complex molecule.
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During the past decade, one of the most important
products developed in Dr. Welch's laboratory has
been C-methylputrescine, the first positron emitting
radiopharmaceutical for tumor location, which has
been used successfully in detecting carcinoma.
The C-palmitate developed in Dr. Welch's laboratory is another radiopharmaceutical involving new
and creative cyclotron radiochemistry and is now
being used for routine diagnostic PETT imaging, and
for the measurement of myocardial metabolism.
Demonstrating the clinical efficacy of radiopharmaceuticals such as these, Dr. Welch has facilitated the
transition of nuclear medicine away from the determination of organ structure towards the measurement
of organ function.
Washington University has been a Specialized
Center of Research for thrombosis for ten years, and
one major area of achievement has been the success
of Dr. Welch and his co-workers in developing
pharmaceuticals for studying coagulation disorders.
The ln-111 research at Mallinckrodt Institute revolutionized the methodology for labeling cells and
introduced a whole new class of radiopharmaceuticals
to nuclear medicine. Presently, many other laboratories are imitating Dr. Welch's research program
involving the use of 111 In-platelets for imaging
thrombi and 111 In-leukocytes to detect abscesses
and measure inflammatory response in ischemic
myocardium.

Early in 1970, Dr. Welch began to develop an
interdisciplinary teaching program which today attracts students from across the United States. Prior to
its initiation, a career in radiopharmaceutical chemistry required a Ph.D. degree in hot atom chemistry
followed by an applied post-doctoral fellowship in a
clinical environment. Dr. Welch, in seeking a joint
appointment at Washington University in both radiology and chemistry, altered the educational patterns
of radiopharmaceutical scientists, demonstrated that
the principles of radiochemistry and radiopharmaceutical chemistry could be part of one integrated
program, and served as an early role model for the
interdisciplinary scientist who applies the rigor of
basic science to the solution of practical clinical
problems.
Having worked in Dr. Welch's laboratory as a
post-doctoral fellow, Kenneth A. Krohn, Ph.D., Associate Professor of Radiology and Acting Director of
Nuclear Medicine at the University of California,
Davis, comments in a letter supporting the nomination on the dominant role Dr. Welch has played in
training graduate students, post-doctoral fellows, nuclear medicine residents, and sabbatical academicians.
Included among those scientists are Michael D.
Loberg, Ph.D., Director of Pharmaceutical Research,
Squibb Institute; John Harwig, Ph.D., Associate
Professor, U.S.C.; Mathew Thakur, Ph.D., Associate
Professor, Yale University; Linda Knight, Ph.D.,
Associate Professor, Temple University; and James
Frost, M.D., Ph.D., Johns Hopkins University.

Pictured right are former students
and colleagues of Dr. Welch. Left to
right are: Linda Knight, Ph.D.,
Temple University; Barbara Francis,
George Washington University; William Eckelman, Ph.D., George
Washington University; Mathew
Thakur, Ph.D., Yale University;
Maria Straatman, M.S., Cyclotron
Corporation; and Kenneth Krohn,
Ph.D., University of California.
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Aebersold Award
The Paul C. Aebersold Award honors the memory
of a man who was responsible more than any other
individual for the acceptance and application of
radioisotopes in this country. Dr. Aebersold was a
member of a group of scientists under Professor
Ernest Lawrence at Berkeley who developed the
cyclotron in the early 1930s. He later participated in
the production and application of the first radioactive
material administered to human beings. Assigned to
radioisotope production on the Manhattan Project
during World War II and the subsequent development
of the atomic bomb. Dr. Aebersold directed the first
peaceful distribution and use of radioisotopes at Oak
Ridge, Tennessee. In 1946, Mallinckrodt Institute of
Radiology shared in the use of an isotope for cancer
research when the first unit of radioactive Carbon-14
was released by the War Department to Barnard Free
Skin and Cancer Hospital. When Dr. Aebersold retired
as Director of the AEC Division of Isotopes Development in 1965, as a result of his efforts, radioisotopes
had been applied in the fields of biology, medicine,
industry, agriculture, and many others.
The hallmarks of Dr. Michael Welch's career as a
research scientist—the importance of a good scientific
background, the need to be scientifically adventurous, and above all a propensity for continuing
education—represent a fitting tribute to the memory
of Paul C. Aebersold.

Elected to
Executive Council
Dr. Ronald G. Evens, Elizabeth Mallinckrodt Professor and Director of the Mallinckrodt Institute of
Radiology, Washington University^ School of Medicine, has been elected for a five-year term to the
Executive Council of the American Roentgen Ray
Society.
The twenty-member Council is the governing body
of the Society and includes the officers, the chairmen
of key committees, and five elected members.
The oldest of the American scientific radiological
organizations, the American Roentgen Ray Society
was founded in 1900 in St. Louis with the objective
of advancing medicine through the science of radiology. It gives particular emphasis to significant teaching efforts and contributions of members to medical
literature.
Dr. Evens was appointed head of the Department
of Radiology at Washington University in 1971. He is
past president of the Society of the Chairmen of
Academic Radiology Departments, a Fellow of the
American College of Radiology, and past president of
the Missouri Radiological Society.

Dr. Lin Awarded Grant
Dr. Hsiu-san Lin of the Division of Radiation
Oncology has been awarded $448,053 from the
National Heart, Lung, and Blood Institute to continue his investigation on the biology of pulmonary
alveolar macrophages for the next five years. Dr. Lir
also received a new three-year grant totalinc
$126,220 from the National Institute of Allergy anc
Infectious Diseases to study the origin and differen
tiation of blood monocytes.

Dr. Hsiu-san Lin

1980 Gridiron Proceeds
For Cancer Research at MIR

Ms. Nancy Belt, 1979-80 President of the Advertising Federation of St. Louis, presents the proceeds of the Gridiron
Show to Mr. Edwin B. Meissner, Jr., President of the Board of Directors, Barnard Hospital.
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"Grand Slams," the 46th annual Gridiron Show of
the Advertising Federation of St. Louis, roasting local
personalities and poking fun at the happenings of the
previous year, was staged on March 26, in the
Khorassan Room of the Chase Park Plaza Hotel. The
gala event raised $13,000 for the Barnard Free Skin
and Cancer Hospital, and the funds will be used for
further development of the flow-cytometry facility
operated by the Mallinckrodt Institute Division of
Radiation Oncology, Section of Cancer Biology. This
intriguing new technology, which automatically
identifies and separates different types of cells in a
tissue sample, will greatly speed up the evaluation of
new cancer treatments that may be used in future
patients.
Ms. Nancy Belt, 1979-80 AFSL President, made
the presentation to Edwin B. Meissner, Jr., Chairman
of the Barnard Hospital Board, at a dinner on May 6,
at Stan and Biggies restaurant.

Dr. Carlos Perez, Director
of the Division of Radiation
Oncology at Mallinckrodt
Institute, gave a short slide
presentation describing the
research projects planned
for the flow-cytometry facility.
The total AFSL donation
to cancer research, since
1945, amounts to over
$426,000 and, according to Henrietta Meier, Gridiron
general chairman, the funds raised have been seed
money for matching grants resulting in more than $1
million in contributions to local cancer research.
AFSL's. 207-membership includes individuals with
interests in advertising and public relations.

FLOW CYTOMETRY
New Technology Holds Possibilities for Cancer Research
One of the major strategies in chemotherapy is to use two
drugs in combination. The first drug kills some of the cells, but
also arrests the remaining cells in a phase where they will be
sensitive to a second drug. Flow cytometry with DNA staining
and life cycle analysis is being used to determine which cells
were killed by the first agent and, therefore, which cells
comprise the target populations for the second agent. This
information will enable lower doses of drugs to be administered while maintaining high levels of tumor cell killing and
thus contribute significantly to improved combination anticancer drug therapy.
A number of human tumors such as from breast, uterus and
prostate are dependent upon specific hormones for their
growth. Prior to the advent of flow cytometry, it was no;
possible to isolate those tumor cells that were hormone-sensitive even though their presence in the tumor and their content
of specific hormone receptors was known. The development of
fluorescently-tagged hormones such as estrogen and progesterone permits detailed studies of their binding to those target
tumor cells expressing the appropriate receptors. Furthermore,
the isolation of these cells by flow cytometry and their growth
in tissue culture is being used to determine whether they are
the same cells responsible for the growth of the tumor.
Immunotherapy is a promising area of cancer research that
involves studies of our body's normal defense against malignant cell growth with the goal of boosting this anticancer
action to eradicate tumors completely. Flow cytometry
together with the development of many highly-specific membrane labels for a host of different types of immune cells is
making possible for the first time detailed studies of their
interaction with malignant cells within tumors.
It is clear that potential applications of the technology are
multiple, being restricted solely by scientific ingenuity. Flow
cytometry is so new and different from conventional methods
of cell analysis that the full realization of its potential
presently lags behind its capabilities.
Multiparameter cell analysis is bringing together cell biologists and clinicians as well as physicists and computer experts
in an increasing number of the leading research and treatment
centers in the world that now have this capability. The new
Flow Cytometry Facility places us on the leading edge of new
developments in this important area. It serves as a focus for
many of the activities and interests of the Division of
Radiation Oncology and creates opportunities for fruitful
collaboration with researchers throughout Washington University. Since the Flow Cytometry Facility is the first of its kind
in the Bi-state region, provisions have been made for sharing
this important resource and facility with other cell biologists
and clinical oncologists throughout this region.

The Section of Cancer Biology, Division of Radiation
Oncology has recently purchased a Becton-Dickinson, fluorescent-activated cell sorter (Flow Cytometer). This was made
possible with a generous contribution from the Advertising
Federation of St. Louis. The Flow Cytometer is the heart of
an extensive and newly constructed Flow Cytometry Facility
at 4511 Forest Park Blvd. that is under the direction of Dr.
Alexander Nakeff. The total cost of the unit is $125,000 and
the computer capabilities required to process and analyze the
data are worth an additional $75,000. In addition, the
operation of this facility will cost $94,000 per year.
The Division and Washington University School of Medicine
have firmly committed themselves to the development of this
sophisticated technology, which will greatly contribute to the
cancer research program at Washington University.
Flow cytometry is a new and exciting technology which
applies the most recent advances in electronics and laser
technology to the solution of some of the most basic problems
of cell and tumor biology. A cell suspension must first be
mixed with various fluorescent probes (either dyes or labeled
proteins, for example) which either bind to the membranes of
specific cells of interest or enter them to bind to specific
internal structures such as their nuclei. The cells are then
introduced into the machine in a stream and pass one-by-one
through a laser beam at the rate of thousands of cells per
second. Only those cells containing the dye are excited to emit
a pulse of light. The signal is detected by photo-sensors which
convert this into an electrical signal for storage into computer
memory. Subsequently, the cell stream is charged and broken
into droplets. Only individual droplets containing a single
fluorescently-tagged cell are electically charged and are deflected into collection vessels. Cell analysis and sorting occurs
at rates in excess of 1000 cells per second. The Flow
Cytometer can examine up to 3 parameters per cell simultaneously with an extension to 5 parameters being readily
available. All of the analysis and sorting can also be done
without affecting the viability of the cells collected.
There are a number of major areas where flow cytometry
will have an immediate and substantial impact on the
Divisions' cancer research program. One involves the analysis
of different cell subpopulations which are responsible for tumor
growth within both human and experimental solid tumors.
These can now be separated by flow cytometry based upon
their unique staining characteristics with various fluorescent
probes. They are being studied following either radiation or
drugs or their combination to determine which anticancer
treatments are most effective in arresting tumor growth in the
development of new and better treatments for cancer.
Many anticancer drugs kill tumor cells most efficiently
when the cells are in a drug-sensitive part of their life cycle.
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International Symposium
Michael J. Welch, Ph.D., Professor
of Radiology and Chemistry at the
Mallinckrodt Institute of Radiology,
was Chairman of the Third International Symposium on Radiopharmaceutical Chemistry, hosted by
Washington University, June 16-20.
Over two hundred participants from
twenty three countries, including such
distant points as Peking, Baghdad,
Australia, and South Africa attended.
Papers were presented on topics that
included: all aspects of radiopharmaceutical design and preparation, relevant aspects of radionuclide research
and methodology; problems arising
from the use of radionuclides in
biochemical and biological studies;
and quality control problems relating
to short-lived radiopharmaceuticals.
Others from Mallinckrodt Institute
working with Dr. Welch on the organizing committee were Diane Zaltsman,
Secretary-Treasurer, Dr. M.M. TerPogossian, and Dr. T.J. Tewson. In
addition to the scientific lecture and
poster sessions, the committee planned a social program for the participants and their families that acquainted them with the St. Louis area
and provided them with a taste of its
rich history.

The remarks of Dr. Welch bring smiles to the members of the Founding
Committee of the Radiopharmaceutical Council at the Third International Symposium of Radiopharmaceutical Chemistry. Left to right are:
D.J. Silvester, Ph.D.; A.P. Wolf, Ph.D.; G. Stdcklin, Ph.D.; M.J.Welch,
Ph.D.; I. Cohen, Ph.D.; J.G. Cunningham, Ph.D., invited speaker; and T.
Nozaki, Ph.D.

Dr. M. Maida, Visiting Professor in Radiation Sciences,
right, and Dr. Kojima, Professor of Radiopharmaceutical
Chemistry at Kyushu University, Fukuoka, Japan, enjoy
a barbecue at Wohl Center.

Dr. Michael J. Welch escorts Bo-Li Liu, Associate
Professor of Radiochemistry at Peking Normal University, Peking, China, and a participant in the Third
International Symposium on Radiopharmaceutical
Chemistry on a tour of his laboratory facilities at MIR.

INTERVENTIONAL RADIOLOGY at MIR
Mallinckrodt Institute radiologists are performing
many new interventional radiologic procedures, some
of which may replace surgery. Either alone or as an
adjunct to a surgical procedure, many of these newer
techniques offer the possibility of treating certain
disease situations in less time and with less risk,
discomfort, or cost to the patient. Angioplasty, Local
Thrombolytic Therapy, Arterial Embolization, and
Transhepatic Biliary Drainage are all non-surgical
therapeutic procedures which are extensions of basic
angiographic procedures in use for decades.
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Angioplasty
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Angioplasty, the balloon catheter method for
opening atherosclerotic arteries blocked with plaque,
is an extension of angiography, a procedure used to
locate, identify, and measure arterial disease. The first
balloon catheter for treating atherosclerotic peripheral vascular disease was introduced by Charles
Dotter in 1964 and demonstrated the potential of the
technique in treating arterial obstructions. In the
mid-1970's, Dr. Andreas Gruntzig of Switzerland
modified and refined the Dotter catheter by developing a balloon that could be inflated in a controlled
fashion to a predetermined size. Griintzig's modification was the breakthrough that has made percutaneous balloon angioplasty possible today.
In the last two years, Mallinckrodt radiologists Drs.
Louis Gilula, Bruce McClennan, along with Drs.
William Totty and Robert Stanley have performed
over 60 peripheral and renal angioplasty procedures.
Dr. Philip Ludbrooke anticipates the use of coronary
angioplasty in the near future.
Dr. Gilula explained the diagnostic procedure:
"The radiologist inserts a catheter into the femoral
artery and, under fluoroscopic guidance, positions it
near the site of the stenosis or blockage. Angioplasty
is then performed to open the vessel." Dr. Gilula
considers the ideal candidate for peripheral angioplasty as "one with peripheral vascular disease who
experiences leg pain after walking less than one block,
or has a non-healing foot or ankle ulcer." Dr. McClennan describes the ideal candidate for renal angioplasty
as "someone with documented renal vascular hypertension caused by renal artery stenosis." "Angioplasty may be performed in older patients to preserve
renal function." said Dr. McClennan.
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Angiogram shows occlusion of popliteal artery with small
collateral vessels filling the distal leg.

For angioplasty, the radiologist threads a catheter
equipped with a balloon that will be inflated to a
pre-determined controlled diameter when it reaches
the blockage in order to compress the plaque and
stretch the blood vessel to its former diameter. The
balloon is then deflated and blood pressure is
measured at the site to determine whether or not the
newly created opening affords adequate blood flow;
if not, the angioplasty procedure can be repeated.
"The effect is usually evident immediately," said Dr.
Gilula. "Patients with peripheral vascular disease
experience relief of pain, may walk the next day, and
are usually out of the hospital in three days."
According to Dr. McClennan, renal vascular disease
patients often show improved blood pressure on the
treatment table and can be out of the hospital in two
to four days. After treatment, continued small daily
doses of aspirin help to offset any tendency to clot.
In a study reported by Gruntzig et al, 87 percent of
the patients with good initial treatment results have
their treated artery still open after two or more years.
If the condition recurs, the patient can be re-treated
with either angioplasty or surgery.

Thrombolytic Therapy

Transcatheter Arterial Embolization

Until recently, when angiography revealed that
arterial obstruction was due to a clot or thrombus,
treatment usually involved immediate surgical removal—a method not always technically feasible.
Recently at Mallinckrodt Institute, Drs. Gilula,
McClennan, and Totty have begun to treat selected
patients with a new local intravascular method of
Thrombolytic Therapy. Dr. Totty explained, "This
method involves placing a catheter into the blocked
artery. With the catheter tip just above or into the
thrombus, very small amounts of a clot dissolving
drug (streptokinase or urokinase) are directly infused.
By using small amounts of the drug many of the
problems associated with generalized intravenous
treatment can be avoided. Several patients have now
been successfully treated, including one patient with
a totally blocked distal aorta."

Since 1975, using an interventional method called
Transcatheter Arterial Embolization, Dr. Robert
Stanley and Dr. William Murphy have collaborated on
the therapeutic treatment of over a dozen patients
with a variety of soft tissue malformations ranging
from lesions in the pelvis to lesions in the tip of the
finger. The malformations, clusters of abnormal
vessels developed into a communication between an
artery and a vein, are unusual lesions that sometimes
behave like tumors, but are actually benign nontumorous entities. "They are usually congenital in
origin or develop following penetrating trauma such
as a gunshot wound," said Dr. Stanley. "After
diagnosis by arteriography, we place a catheter
directly into the feeding vessels, then inject minute
particles of thrombogenic material into the bed of the
arteriovenous malformation to obliterate the vascular
spaces. The embolization agent we prefer to use
today is a polyvinyl alcohol sponge which remains
within the body and permanently obliterates the
abnormal vascular tumor bed."
These arteriovenous malformations are present in
growing children and the long term effect of treatment can only be assessed over a period of years. For
example, excessive growth of a leg may be associated
with the presence of soft tissue vascular malformation. In order to determine whether or not the
embolization procedure has adequately reduced the
malformation, subsequent growth of the legs must be
monitored carefully until the child's normal growth
period is completed.
Dr. Murphy added, "In the majority of cases we
have treated, the results have been most gratifying.
Large, deforming, and sometimes intermittently
bleeding lesions have been well controlled for a
period of several years, eliminating the need for
radical surgery. We are currently following six patients in various stages of this embolization therapy
program who are being treated for a variety of
lesions." With the results already evident, Dr. Stanley
and Dr. Murphy feel that the technique of transcatheter embolization of large chronic arteriovenous
malformations in the trunk and limbs should be given
consideration as the primary form of treatment when
the dominant arterial feeder(s) can be clearly identified and subselectively catheterized. This technique
offers the potential for sparing the patient extensive
surgery.
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After a 24-hour streptokinase infusion, the vessel has
opened and the area of narrowing is again seen. An
angioplasty was subsequently performed. The patient is
now doing well after four months.
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INTERVENTIONAL RADIOLOGY
under local anesthetic, involves threading a multiholed catheter into the liver. The radiologist attempts
to lace the catheter through the blockage and
establish internal bile drainage to the duodenum. If
the obstruction is impenetrable, the catheter establishes a channel to drain bile externally. The patient
can usually be discharged in a week to ten days.
Dr. Weyman stresses that while surgery is still the
primary corrective treatment, the percutaneous drainage is a desirable palliative procedure to restore bile
drainage and alleviate the affects of restricted bile
flow. Occasionally radiologists establish transhepatic
biliary drainage to improve the patient's condition
preparatory to corrective surgery. In five months, Dr.
Weyman has installed two external and three internal
biliary drainage catheters.
Whether these various interventional procedures
serve as complements to surgery, options to surgery,
or as potential primary treatment methods, they
continue to widen the scope of patient treatment at
the Mallinckrodt Institute of Radiology.

Dr. Mokhtar Gado, Mallinckrodt neuroradiologist,
has utilized embolization techniques since 1971 to
treat vascular malformations supplied by intracranial
blood vessels, vessels of the head and neck, and tumors in the region of the pharynx, paranasal sinuses,
tongue, face, or neck.
He explained, "The technique depends upon the
high blood flow in the abnormal vessels causing the
emboli to lodge in them rather than in normal vessels.
Therefore, more and more of the abnormal vessels are
obliterated during the procedure." Dr. Gado expects
new developments in this area to broaden the application of current procedures.
Transhepatic Biliary Drainage
Percutaneous Transhepatic Biliary Drainage is an
interventional technique Dr. Philip Weyman has used
to restore bile drainage in patients whose bile flow is
inhibited by unresectable biliary obstruction, such as
pancreatic cancer, metastatic disease, cancer of the
biliary duct, or surgically unapproachable benign
structures. The percutaneous procedure, performed

New Computer Technique Expedites Patient Service
In the present age there seems to be a computer for
almost everything—from checking out groceries to
doing library research. At Mallinckrodt Institute,
computers play a powerful role in enhancing the
quality of patient care and making the operation of
the Institute more efficient and more productive.
The Diagnostic Computer Section, under the direction of Dr. Gilbert Jost and Rex Hill, M.S., is making
a dramatic contribution to patient care through the
use of optical reading techniques to track the points
of each patient's progress through the Institute—from
moment of arrival to moment of departure. "The
technique, which is similar to the one used in food
markets, is reliable, accurate, and quick to do," said
Dr. Jost. A floor receptionist first logs the patient
arrival time in the computer terminal by passing a
computer wand over the x-ray requisition number.
After the x-ray has been taken, the technologist
registers completion time in a second terminal and
sends the film to the quality control technologist,
who, after approving film study quality, registers
finish time in a third terminal. The receptionist then
registers patient departure time in the computer.
In order to provide a complete record of the
patient's visit to the radiology department, the times

of the following additional events are captured:
1. When old films are matched with new and made
available for reading by the radiologist.
2. When films have been read and can be returned
to the film library.
3. When the radiologist's dictation is transcribed,
the report signed and made available for distribution.
According to Mr. Hill, statistics will be drawn from
data accumulated on a continuing basis over a period
of time. These statistics will aid in defining patterns
and isolating problem areas. In addition, current
information will be available on terminals at floor
supervisors' desks. With pertinent data available and
the names of patients who have waited over 30
minutes on display, supervisors will be better able to
direct attention to delays and schedule problems as
they occur. This data will also be available at inquiry
stations in the department. For example, a physician
coming to the MIR film library area can be accurately
informed of the status of a patient currently undergoing an examination.
"This application of a bar code technique is unique
to Mallinckrodt," says Dr. Jost, "but it should prove
to be a useful method for serving patients faster and
more efficiently."
10

China Officials Visit Mallinckrodt

"Everywhere we go we are met with
smiling faces," Wang Chubin, head of the
six-member delegation from the People's Republic of China, said through their interpreter
on a recent visit to Mallinckrodt. This first
official visit was part of a St. Louis-Nanjing
(Nanking) "sister city" relationship which was
established in October, 1979, and is the
nation's first such relationship with a Mainland Chinese city.
Dr. Lewis J. Thomas, Jr., Director of the
Washington University Computer Laboratory,
was in charge of the tour which included
activities at the medical center relevant to the
interests of the group. Dr. Barry Siegel hosted
a tour of Nuclear Medicine Facilities and Dr.
Michel Ter-Pogossian demonstrated the PETT
VI (positron emission transaxial tomograph)
in the Division of Radiation Sciences. The
PETT VI is the first in the PETT series to use
cesium fluoride crystals as detectors, making
it the fastest such detection system in the
world for providing striking views into the
living human brain.
Zhou Bofan, a vice-chairman of the Nanjing
Municipal Revolutionary Committee said that
he was most impressed by the modern diagnostic equipment such as the PETT and the
CAT Scanner at Mallinckrodt Institute.

Dr. Michel Ter-Pogossian, far right, is pictured at the PETT VI with three
members of the Nanking delegation; translators, Shirley Cheng and
Jing-Shiang Cheng of the Biomedical Computer Laboratory; Dr. Lewis J.
Thomas, back left; and Mr. Edmund Greene, back right, of the
Sister-City Committee.

Dr. Barry Siegel describes activities within Nuclear Medicine to the
visiting group and Mr. Frank Murphy of Mallinckrodt, Inc.

11

V

„•*>*

J X Vir^l

j
%

|?l

/-

y

£
jj&*

J

^t *■

J

A

Residents' Farewell
On the evening of June 23, the
Washington University Alumni Club was
the scene of a convivial gathering of
MIR staff members and residents and
their spouses to celebrate the completed
residency training of Drs. Baron, AufderHeide, Bishop, Brinkley, Howard
Glazer, Monsees, Oakley, and Totty,
and the year's fellowship of Dr. Balfe.
Following cocktails and hors d'oeuvres
in the main lounge, the 90 guests were
seated in the spacious dining room
overlooking the Arch and the St. Louis
riverfront. Dr. David Hardy, ChiefResident, 1980-81, presided and Dr.
Ronald Evens, after congratulatory
remarks, presented each honoree with a
commemorative brass plaque.
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Foreign Lectures
Dr. Robert Stanley presented four lectures at the
5th International Meeting on Body CT in Rome,
Italy, during May 19-23.
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Dr. James E. Marks was invited as a guest lecturer
from the United States to the Third European Clinac
Users Meeting held in the radiation center of Aalborg,
Denmark on May 8-9. He spoke on "The Use of High
Energy X-rays to Spare Normal Brain, Cranium and
Soft Tissues" and "The Use of Electrons to Spare the
Opposite Parotid for Selected Head and Neck Cancers."

Visiting Professors

Awards
Dr. Todd H. Wasserman, Assistant Professor of
Radiology in the Division of Radiation Oncology, has
been awarded a first-year Junior Faculty Clinical
Fellowship of the American Cancer Society for the
period July 1, 1980-June 30, 1981.
Dr. Joseph R. Simpson is a second-year recipient
and Dr. Hywel Madoc-Jones has been awarded the
fellowship for the third year.

C

Panel Member

I Ju

Dr. G. Leland Melson discussed several aspects of
residency training program as a panel member considering Post Graduate Year-1 Options at the Annual
Meeting of the Association of University Radiologists
in Tucson, March 26.
Dr. John Forrest ('71), Chief of Diagnostic Radiology at the University Hospital, UCSD, was a Visiting
Professor in Chest Radiology, June 23-27. Dr. Forrest
was Associate Professor of Radiology at Mallinckrodt
until 1977.

On May 19, Dr. Melson participated in a panel
"Clinical Value of Ultrasonography in Urological
Evaluation" where he discussed the relationship of
ultrasound to other imaging techniques at the Annual
Meeting of the American Urological Association in
San Francisco.

Dr. Bruce McClennan was a Visiting Professor at
the University of Iowa April 28-29.

Scientific Exhibit
Dr. Carlos A. Perez presented a scientific exhibit
on "Cancer Therapy by Hyperthermia, Drugs, and
Radiation" at the Third International Symposium,
held at Colorado State University in Fort Collins,
Colorado.

Dr. Robert Stanley addressed the Greater Kans;j
City Radiological Society and was a Visiting Professcr
at the University of Kansas Medical Center and St.
Luke's Hospital in Kansas City on April 16 and 17.
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Lectures - Symposiums
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Recent talks by Dr. Carlos A. Perez include:
"Organization of Radiation Oncology in the Cooperative Groups," Clinical Cancer Investigation Review Committee, NIH, Bethesda, Maryland.
"Frontiers of Cancer Research," at the First
Community Conference on Cancer Nursing in Ft.
Worth.
"Carcinoma, of the Prostate," Southwestern Medical School, Dallas.
"Cancer of the Uterine Cervix" and "Cancer of the
Prostate," Allegheny General Hospital, Pittsburgh.

lib
Chief Residents
Dr. David Hardy has been appointed Chief Resident for 1980-1981 and Dr. Harvey Glazer, Co-Chief
Resident. Drs. Hardy and Glazer will be working
closely with Dr. Ronald Evens and Dr. Lee Melson in
the operation of the MIR residency training.

Dr. Robert Stanley was a member of the faculty
for an Imaging Seminar at the Hospital of the
University of Pennsylvania, Philadelphia, April 9-11.
Dr. James E. Marks was a member of the faculty at
a workshop sponsored by the University of North
Carolina School of Medicine, March 14, in Chapel
Hill, on Radiotherapy of Primary Malignant Gliomas.
He spoke on "Review of Studies of Radiotherapy of
Malignant Gliomas" and "Mechanisms of Evaluation
of Response to Therapy."

Honored

V

Dr. Jill White, second year resident, has been
elected the MIR Housestaff Representative to the
Barnes Hospital Advisory Committee for the 1980
academic year.

Dr. Patrick R. M. Thomas presented a talk on
"Prospective Film Review in a Clinical Trial Involving
Radiotherapy," at the American Society of Clinical
Oncology, May 27, in San Diego.

CALENDAR OF EVENTS
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Dr. Robert Stanley addressed the American Association of Anatomists in Omaha on April 30 during a
forum in applied anatomy.

July 11-17, 1980
AMERICAN SOCIETY OF RADIOLOGIC
TECHNOLOGISTS
Atlanta, Georgia
July 13-19, 1980
NATIONAL RADIOLOGIC TECHNOLOGY
WEEK
July 20-24, 1980
AMERICAN MEDICAL ASSOCIATION
Chicago, Illinois
September 21-25, 1980
AMERICAN COLLEGE OF RADIOLOGY
New Orleans, Louisiana
October 21-25, 1980
AMERICAN SOCIETY OF THERAPEUTIC
RADIOLOGISTS
Dallas, Texas
'November 16-21, 1980
RADIOLOGICAL SOCIETY OF NORTH
AMERICA
Dallas, Texas

Dr. Carlos A. Perez presented three lectures as a
member of the faculty for a refresher course sponsored by the University of Minnesota in Minneapolis,
May 21-23. His subjects were:
(1) Current Clinical Status of Hyperthermia,
(2) Periaortic radiation and Prostate Cancer, and
(3) Irradiation of Lung Cancer Techniques and
Results.
Dr. Barbara B. Sterkel presented "Persistent Renal
Activity Seen in Gallium Scans in Patients with
Severe Hepatocellular Disease" at the 27th annual
meeting of the Society of Nuclear Medicine, June
24-27 in Detroit.
Dr. Carlos A. Perez presented "Medical Aspects of
Treatment Planning in Lung Cancer" at the American
Association of Physicists in Medicine, July 28, in
Minneapolis.
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Cancer Workshop
-*>
Drs. Theodore Phillips (left) and
Todd Wasserman (right), speakers
at the May 1 Cancer Workshop,
with Dr. Carlos Perez, Director of
the Division of Radiation Oncology.

which would lack the neurotoxicity. Currently there
are nine active clinical Phase II trials involving
Misonidazole underway in the United States and
other trials underway in England, Canada, and other
countries. Preliminary data suggests that despite the
drug related toxicity, it can be given with high degree;
of safety provided the total drug dose is limited.
There is a suggestion that the use of the drug in
conjunction with radiation increases cancer control of
some tumors.
The second area of new research in cancer therapy
involves the use of drugs that protect the normal
tissues from radiation without protecting the tumor.
A series of compounds was originally developed by
the Army at Walter Reed in Washington, D.C. in an
attempt to protect troops from the threat of radiation sickness. The compounds did not perform as
expected, but were discovered to protect normal
tissues selectively against the effects of low dose
radiation. As a follow-up of extensive laboratory
work on one of these drugs, called WR-2721, and its
protective effects against the bone marrow toxicity of
chemotherapy agents, Drs. Phillips and Wasserman
will participate in the first clinical trial of this drug in
the United States sometime in the summer of 1980.
The clinical staff of the Division of Radiation
Oncology will be seeking participation of patients and
referring physicians in the ongoing clinical trials of
both the radiosensitizers and the radioprotectors.
Dr. Phillips and Dr. Wasserman, who currently hava
authored several papers on the subject of their
research, are advisors to the National Cancer Institute
for development of further research in this area. The ^
were recently featured at a meeting organized as
conference on radiation sensitizers and protector:
held in Key Biscayne, Florida.

At a recent Cancer Workshop, sponsored by the
Division of Radiation Oncology of the Mallinckrodt
Institute of Radiology, the subject of radiosensitizers
and protector agents in cancer therapy was discussed
by Dr. Todd H. Wasserman, Assistant Professor,
Division of Radiation Oncology and Dr. Theodore L.
Phillips, Professor and Chairman, Department of
Radiation Oncology, University of California Medical
Center, San Francisco. Dr. Wasserman, who worked
with Dr. Phillips for three years prior to coming to St.
Louis to join the staff of Mallinckrodt, was awarded
the 1978 Resident Essay Award of the American
Society of Therapeutic Radiology for his work with
radiosensitizers. The subject of the workshop was the
use of drugs that have no direct effect on cancer but
modify the effect of ionizing radiation on cancer.
Currently being investigated are two classes of
drugs. The first type, those which sensitize tumor
cells to radiation but do not sensitize normal tissues
increase the selective ability of radiation to kill cancer
cells without increasing the toxicity of radiation.
Laboratory studies began on these drugs in the mid
1970's and clinical trials in the United States began
with a drug called Misonidazole in 1977. Conducted
primarily through the Radiation Therapy Oncology
Group, the trials were initially done at the University
of California at San Francisco and are now being
conducted at Washington University by the Division
of Radiation Oncology. The sensitizers work by
increasing the killing potential of radiation on cancer
cells. Early clinical trials with Misonidazole on several
hundred patients have offered promising results,
although there are limitations of its use because of
some drug related side effects on the nervous system.
There is an increasing effort by chemists and pharmacologists to develop other analogs of this drug
16
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Hyperthermia, high body temperature induced for
therapeutic purposes, was first documented in 1866
as effecting tumor regression, yet only in recent years
with the development of new technology, has it
become a viable treatment modality. Whether induced by hot water baths, ultra-sound waves, low
radiofrequency waves, microwaves, heated blood perfusions, or delivery of heated anesthetic gases to the
lungs, hyperthermia temperatures of 107.6° to 113°
tend to kill cancer cells but leave normal cells less
affected. Cancer cells are more susceptible to heat
because of their proliferating nature, poor circulation,
poor nutrition, and characteristic inability to cool. In
addition, cancer cells appear to be less able to repair
from treatment by conventional methods if they are
combined with hyperthermia. Radiotherapy, for example, is 40% to 60% more effective when combined
with hyperthermia.
In a recent television interview in the Division of
Radiation Oncology of Mallinckrodt Institute, Dr.
Carlos Perez, Director, Dr. Walter Kopecky, and one
of their patients, Mr. Robert Siemer, discussed the
procedure during an actual treatment session. Mr.
.Siemer, who was being treated for cancer with
microwave hyperthermia following a complete series
of radiotherapy treatments, said he experienced only
mild discomfort, initially from the insertion of
probes, then from the five-minute period of heat rise.

and finally from the ninety-minute duration of
treatment.
To begin the procedure, Dr. Perez inserted one of
two small probes into the tumor core; the other, into
superficial normal tissue. He explained that the
probes are inserted without anesthetic because probe
insertion is no more painful than anesthetic injection.
Then, while the microwave transmitter was being
aligned with the tumor and the controls were being
set, Mr. Siemer described his treatment, "Other than
an occasional mild burn and the discomfort of lying
on a hard surface, I have found the procedure to be
nearly painless." Dr. Kopecky, indicating dials on the
monitor, added, "The gauges show the temperature
being measured by the probes, but Bob alerts me if
any particularly strong heat sensation occurs." Having
nearly completed the hyperthermia treatment series,
Bob Siemer spoke from experience, "I usually just
relax and take a little nap."
Microwave hyperthermia treatments are performed
at Mallinckrodt Institute more frequently than at
most other hospitals in the country, and approximately 80% of the patients treated here in the last
two years have experienced significant tumor reductions. Dr. Perez stressed, however, that reduction
does not translate to cure. "The procedure is still in
the investigative stage, with only the potential for
cure."
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New Technique
To Help Predict Patient Response To Endocrine Therapy
"hormone receptors" in its cytoplasm. This is more
easily said than done, for current methods have been
time-consuming and have yielded unacceptably high
numbers of false-positive and false-negative cases.
Dr. Rao and his associates have developed a
technique which promises to simplify the identification of hormone-responsive tumors and improve the
reliability of previous assay procedures. He uses
fluorescein to label sex steroid hormones (specifically, estrogen and progesterone). These labeled hormones are incubated with a tumor tissue sample, and
count the number of cells to which they bind.
This technique eliminates some of the technical
impasse which has previously impeded the prediction
of the response of tumor-to-hormone therapy. Much
remains to be done, however. Investigators must
closely follow those patients whom the assay has
singled out as prime candidates for hormone therapy;
such studies will reveal how closely the assay's
prediction correlates with the patient's response to
endocrine therapy. Also, using the Division's new
flow cytometry facility (provided by contributions of
the Advertising Federation of St. Louis), Dr. Rao and
his associates will refine their procedures for quantifying the fluorescence and for counting the cells to
which hormones will bind. If Dr. Rao's technique is
as effective as it appears to be, it may contribute
significantly to the treatment of breast, prostate,
uterine, and renal cancers.

Hormone therapy has long been a treatment option
for certain types of cancer but, until recently, its
track record has been less than impressive—only one
patient in three has benefited from hormonal manipulation. This statistic is due not to any major shortcoming of hormonal therapy itself, but rather to the
inability of physicians to predict which tumors will
respond to this kind of management. Even after
recent work which increased the response in breast
cancer patients to between 50% to 60%, there was still
a glaring need for a more reliable way to predict a
tumor's hormone-responsiveness. Now, B.R. Rao,
Ph.D., Mallinckrodt Institute Section of Cancer Biology, and his co-workers have given good reason for
optimism regarding uncertain future of hormone
therapy. Dr. Rao's new technique for detecting
hormone receptors may well be the key to predicting
accurately which tumors will respond to hormonal
manipulation.
The rationale behind hormone therapy is relatively
simple. In certain normal cells, steroid hormones are
essential for normal cell growth and protein synthesis.
When cells undergo the transformation from normalcy to malignancy, they may or may not retain this
hormone dependency; if they do remain hormonedependent, "ablative" hormone therapy (i.e., deprivation of necessary hormones) will interfere with their
growth and eventually lead to tumor regression.
One way of determining whether a tumor cell is
hormone-dependent is to check for the presence of

RESIDENTS, FELLOWS & TRAINEES 1979-1980

Back row, left: Drs. Balfe, Ling, Thaler, Totty, Brinkley, Scales, Vannier, Stein, Johnston, Bauer, Machefsky, Glazer,
Chandra-Sekar. Center row: Drs. Yu, Glazer, Lenobel, Spies, Engelstad, AufderHeide, Bishop, Nicol, Miller, Monsees,
Odrezin, White. Front row: Drs. Cintron; McDonald; Hardy; Sterkel; Melson; Baron, Chief Resident; Evens,
Radiologist-in-Chief and Director of MIR; Oakley, Co-Chief Resident; Palmer; Kopen; Reed; Wahl.
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Monte Carlo Seminar

Dr. William Murphy spoke on
"Forearm and Hand Arteriography" to the 125 participants.
A view of Monte Carlo harbor.
The second annual continuing medical education program,
sponsored by the Mallinckrodt Institute of Radiology under
the direction of Drs. Louis Gilula and William Murphy was
held at the Loews Monte-Carlo hotel complex on the French
Riviera, May 3-12. Dr. William McAlister was also a member of
the faculty of distinguished American and European physicians who presented current concepts in musculoskeletal
radiology and orthopedics.

Following the symposium. Dr. Emily Smith visited
Florence and Rome, Italy. Here she stands by the
majestic doors to the Church of Santa Croce (Sacred
Cross) in Florence.
Dr. and Mrs. Charles Hobby of Valdosta, GA visit the
Royal Palace of Prince Ranier and Princess Grace of
Monaco.

TECHNO

Addresses Top Radiologic
Technology Meeting

t

Authors Nuclear X-ray Atlas

Glenn P. Glasgow, Ph.D., Assistant
Professor in Radiation at Mallinckrodt
Institute of Radiology and Washington
University, spoke on "Quality Assurance
\ in Radiation Therapy" at the 52nd An^
nual Meeting of The American Society
^
of Radiologic Technologists, July 11-17,
■k \ in Atlanta.
Dr. Glasgow joined the staff at Mallinckrodt
Institute in 1974 as a Post-Doctoral Fellow. In 1975
he became an instructor in Radiation Physics in
Radiology, eventually moving to his present Assistant
Professor post. He will be one of the 38 important
health care professionals invited to address this
scientific gathering of over 3,000 radiologic technologists.
The ASRT Atlanta Annual Meeting will provide
educational opportunity to diagnostic radiographers,
radiation therapy technologists, nuclear medicine
technologists, and diagnostic medical sonography
technologists from across the United States.
Also offered at this professional gathering will be
scientific displays, 32 symposia and seminars, and
over 100 commercial exhibits.

Radionuclide Imaging Artifacts, an atlas of nuclear
x-ray images compiled by Donald R. Bernier,
C.N.M.T., of the Nuclear Medicine Division of Mallinckrodt Institute of Radiology and L. David Wells,
C.N.M.T., of the Nuclear Medicine Division at University Community Hospital in Tampa, illustrates unusual problems associated with radionuclide imaging /
The authors intend for the book to serve as both an
educational document and a practical reference tool
when technical problems occur. They hope that
sharing these images will result in an overall improvement in quality control and in the quality of nuclear
medicine practice.
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Norman Hente, R.T., lectured on "Preparing Scientific Exhibits" at the March meeting of the 7th
District (Therapy) MSRT. He also spoke on "Photography in a Radiology Department" at the Gateway
Chapter regional meeting of the Biological Photographers Association held at MIR on March 22.

Dr. Barry A. Siegel presented a talk on "Radionuclide Renal Studies" at the annual meeting of the
Technologists' Section of the Society of Nuclear
Medicine, February 6-8, in Louisville, Kentucky.
Deborah Christensen, C.N.M.T., was awarded first
prize in the Scientific Papers Division for her presentation, "A Technique for Performing Simultaneous
Ventilation-Perfusion Studies Utilizing Kr-8/M gas
and Tc-99m MAA."

Opposite page
Barbara Hente demonstrates her technique of chest compres
sion on "Resusci-Annie" while Norm Hente practices rescu.
breathing. This special recording mannequin records hov
much air is being blown into the victim's lungs and beeps if tht.
student's hands are placed at a spot on the chest that woul(
cause a cracked rib. Lights flash to indicate too much pressun
applied.
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Top Honors
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CPR Workshop at MIR
Eleven MIR employees were among 28 members of
the 4th District of the Missouri Society of Radiologic
Technologists who participated in a two-day workshop in April leading to certification in CPR (cardiopulmonary resuscitation) by the St. Louis Heart
Association. Linda Kratz, R.N., of the MIR nursing
staff was one of six certified instructors. The seminar
l
(7 E.C.E. points) included a slide lecture, movie,
practical demonstrations, and hands-on experience.
The training combines a procedure of chest compression and mouth-to-mouth breathing to keep
blood and oxygen flowing through the body until the
victim can receive more sophisticated cardiac care in
an ambulance or hospital.

High school senior, Cynthia Hegg with her prize-winning
myeloma exhibit.

Cynthia A. Hegg, a senior at Parkway West High
School in St. Louis County, received top honors at
the 1980 Monsanto/Post Dispatch Greater St. Louis
Science Fair, for her research into the effects of a
number of anticancer agents on a murine myeloma
that closely parallels human multiple myeloma. During five months of collaborative work with Mr. Dean
Coulter in the laboratory of Dr. Fred Valeriote in the
MIR Section of Cancer Biology she compared lifespans of treated tumor-bearing mice with those of
untreated controls, while simultaneously measuring
the toxicity of the drug dosages in normal mice.
Protocols based on positive results of these and other
studies will be developed at the Washington University Medical Center over the next few years.
Cynthia's exhibit, on display at the Museum of
Science until Spring, 1981, reflects the analytical
thought, scientific content, and research excellence
stressed by the awarding institutions. Among her
awards were a $4000 scholarship from Monsanto, the
Curator's Scholarship for Tuition and Fees from the
University of Missouri, and a $200 scholarship from
the Medical Society of Greater St. Louis. In addition,
Cynthia received the Blue Award in the Honors
Division of the Science Fair and certificates of
achievement from the American Cancer Society and
the United States Air Force.
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In her nature classes at St. Louis Children's Hospital, Dorothy Evans
combined her love of gardening with her love of the young patients.
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She Had Magic

9?

I met Dorothy Evans only a few months ago, when
she was a patient in the Division of Radiation
Oncology at Mallinckrodt Institute. I found myself
thinking about her a great deal. There was some
special quality about her-a certain zest for life and
loving in her eyes-that had touched my heart and my
imagination. I saw her in the midst of young
professional women from the hospital staff, laughing
mischievously, her eyes sparkling with good humor
and warmth; I saw her talk about her "greenhouse"
project at St. Louis Children's Hospital with the
affection of a parent; I saw her look at John, her
husband of 39 years, with real devotion and understanding. I saw her radiantly happy as she visited with
her son, John who was to receive his Ph.D. in Public
Health from Harvard University in late spring; I saw
her interest quicken as someone mentioned one of
her many friends, whether it be her daily walking
partner (3 to 5 miles each morning), a devoted
neighbor, or a long-time associate with volunteers at
Missouri Botanical Garden. I also saw Dorothy
sleeping in a hospital bed, her husband sitting quietly
beside her, and hovering in the ceiling a brightly
colored enormous helium balloon bedecked with
multi-colored ribbons and bearing the greeting,
"Happy Easter." Dorothy died of multiple myeloma
on April 21, 1980.
Three years before her death, Dorothy played a
fast game of tennis four times a week, walked 13
miles to the Arch from her home in Kirkwood, and
during her 12 years as a Volunteer Nature Therapist at
St. Louis Children's Hospital, Dorothy touched the
lives of many young patients, combining in one
project her love of nature and gardening with her love
of children.
In the beginning, Dorothy had only a few plants to
use in her classes, and so each Sunday, she gathered
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"Word Of Comfort"
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plants and wild flowers for the hospital-bound children from the Evans' farm in St. Francois County.
Through the years, as a result of her tireless efforts
and in spite of setbacks caused by lack of space, her
project grew from a modest roof-top vegetable garden
to a real greenhouse in which to hold her classes.
Construction was done by John Evans and his
neighbors and associates; Huntleigh Hills Garden Club
contributed time and money; Dorothy's Alumnae
Club of Stephens' College provided the sink; and
jnding came from grateful parents of hospitalized
:ungsters. The greenhouse, dedicated in November
79, was the story of love, labor, and determination
1 the part of one Dorothy Evans—indeed, a dream
lat came true.
Three years ago, Dorothy experienced severe rib
lain during a tennis game—the first indication of
nultiple myeloma, a bone marrow malignancy. In
iis disease the malignant plasma cells in the bone
arrow cause many areas of bone to be resorbed,
ading to soft and fragile bones and a high incidence
pathologic fractures.
In her valiant fight against cancer, Dorothy underwent a program of chemotherapy and spinal surgery,
and multiple courses of radiotherapy in the Division
if Radiation Oncology at Mallinckrodt Institute of
Radiology. Even after suffering a loss of hearing from
, tumor in the nerve center at the base of the skull,
Dorothy continued to conduct her weekly classes at
Children's Hospital until December 1979.
Just as during the years Dorothy provided therapy
to many children through her patience, love, and
knowledge of plant and gardening, the example of her
own life of courage and determination became
therapy to people around her, inspiring others to be
brave and strong. We are grateful for having known
her.

Fred Bingaman with Joy Van Dyke awaiting an X-ray on
the fifth floor of Mallinckrodt.
"Most children like grandfathers," says Fred Bingaman, a 77-year-old grandfather, who has been a St.
Louis Children's Hospital volunteer transporting children for pediatric X-ray at Mallinckrodt for four
years. He feels that the "grandfather image" helps
him in what he considers the most important aspect
of his job—comforting and reassuring frightened
children. The measure of Mr. Bingaman's success is
reflected in the smiling faces of the children.
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'Teaching Goes Or
During a spring power failure at the Medi
Center, Dr. Robert C. McKnight showed ingenu
persistence, and dedication as he utilized
nearest available window light for reviewing <
diovascular films with radiology residents,
Floyd Scales, left, and Michael Vannier, cei
(Photo by Dr. William Totty)
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